



0360
(4)


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY DKT. : CM2-104033-006)
APPLICANT : Kirk M. Maxey, *et al.*)
SERIAL NO. : 09/776,574)
FILED : February 1, 2001)
FOR : Internal 1,15 Lactones of Fluprostenol)
and Related Prostaglandin F_{2α} Analogs)
and Their Use in the Treatment of)
Glaucoma and Intraocular Hypertension)

Assistant Commissioner For Patents
Washington, D. C. 20231

CERTIFICATE OF MAILING

The undersigned hereby certifies that this document has been forwarded via First Class Mail, postage prepaid mail to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on March 23, 2001.


Benita J. Rohm, REG. NO. 28,664

INFORMATION DISCLOSURE STATEMENT

SIR:

In compliance with the duty of disclosure according to 37 C.F.R. §1.56, §1.97, and §1.98, Applicant presents herein prior art references which are believed at this time to be relevant to the subject matter of the instant patent application. A copy of the references, which are listed in the annexed PTO-1449 (equivalent) form, is enclosed.

This Information Disclosure Statement is being filed prior to the issuance of a first Office Action for the application. Accordingly, no fee is necessary.

INFORMATION DISCLOSURE STATEMENT
USSN 09/776,574; CM2-104033-006

Should a fee be necessary, the Commissioner is authorized to charge Deposit Account 50-0720 as required.


In view of the foregoing, it is respectfully requested that the Examiner examine the present application, allow the claims, and pass the application for issue. If the Examiner believes that the prosecution of this case can be expedited by a telephone interview, the Examiner is requested to call the undersigned attorney at the telephone number indicated hereinbelow.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Benita J. Rohm", with a long horizontal flourish extending to the right.

Dated: March 23, 2001

Benita J. Rohm
Rohm & Monsanto, P.L.C.
660 Woodward Avenue
Suite 1525
Detroit, MI 48226
Telephone (313) 965-1976
Telecopier (313) 965-1951



LIST OF PRIOR ART CITED BY APPLICANT

PTO-1449 (EQUIVALENT)

Atty Docket:

SN:

Applicant:

Filing date:

Sheet 1 of 1

CM2

09/776,574

Maxey, *et al.*

02/01/01 Group: n/a

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	REF.	DOCUMENT NO.	DATE	NAME	CLASS / SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5,665,773	09/09/97	Klimko, <i>et al.</i>	514/530	12/18/96
	AB	4,599,353	07/08/86	Bito	514/530	05/03/82

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	REF.	DOCUMENT NO.	DATE	COUNTRY	CLASS / SUB CLASS	TRANSLATION YES / NO
---------------------	------	--------------	------	---------	----------------------	-------------------------

NONE

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, etc.)

EXAMINER INITIAL	REF.	
	AC	Fürstner, <i>et al.</i> , Ring-Closing Alkyne Metathesis: Application to the Stereo-selective Total Synthesis of Prostaglandin E ₂ -1,15-Lactone, <i>Angew. Chem. Int. Ed.</i> , 39:7, pp. 1234-36 (2000)
	AD	Lindén, <i>et al.</i> , Prostaglandin Analogues in the Treatment of Glaucoma, <i>Drugs & Aging</i> , 14:5, pp. 387-98 (1999)
	AE	Monograph 4231, <i>The Merck Index</i> , 12 th ed., p. 711 (1996)
	AF	Monograph 5387, <i>The Merck Index</i> , 12 th ed., pp. 918-19 (1996)
	AG	Monograph 8065, <i>The Merck Index</i> , 12 th ed., p. 1354 (1996)
	AH	NDA 21-214 for RESCULA [®] Ciba Vision [®] , p. 2
	AI	Oates, <i>et al.</i> , Clinical Implications of Prostaglandin and Thromboxane A ₂ Formation (First of Two Parts), <i>New England J. Med.</i> , 319:11, pp. 689-98 (1988)
	AJ	Oates, <i>et al.</i> , Clinical Implications of Prostaglandin and Thromboxane A ₂ Formation (Second of Two Parts), <i>New England J. Med.</i> , 319:12, pp. 761-67 (1988)

EXAMINER

DATE CONSIDERED